Literature DB >> 14688058

Human T lymphoblasts and activated dendritic cells in the allogeneic mixed leukocyte reaction are susceptible to NK cell-mediated anti-CD83-dependent cytotoxicity.

David J Munster1, Kelli P A MacDonald, Masato Kato, Derek J N Hart.   

Abstract

CD83 is a marker of dendritic cell (DC) differentiation/activation and its expression in the mouse thymus contributes to CD4(+) T lymphocyte development. Its extrathymic role remains unclear despite the functional effects observed with CD83 fusion proteins or CD83 antibody and recent reports of potential ligands. We investigated the previously observed and presumed functional blockade of the allogeneic mixed leukocyte reaction (MLR) with rabbit polyclonal anti-CD83 (RA83). RA83 inhibition of T lymphocyte proliferation stimulated with allogeneic immature monocyte-derived DC (iMoDC) was confirmed. However, we found it was due to antibody-dependent cellular cytotoxicity (ADCC) mediated by NK cells in the responder T cell preparation. The likely targets of the ADCC were MoDC that had up-regulated CD83 during the MLR. Using a (51)Cr-release assay, we confirmed that CD83(+) MoDC, but not CD83(-) MoDC, are lysed by NK cells in the presence of RA83. However, prior fixation of the stimulator MoDC in the allogeneic MLR did not abrogate RA83 inhibition, indicating that cells from the responder T lymphocyte preparation, involved in the MLR proliferative response, also expressed CD83. We found, after 3-4 days of culture with allogeneic MoDC, a subset of CD3(+) cells had up-regulated CD83 and CD25. These were blasting T cells and, when isolated from the MLR, were found to be lysed by autologous NK cells in the presence of RA83. Thus, CD83 is expressed by responding T cells as well as by stimulating cells in the MLR and both are susceptible to anti-CD83-mediated ADCC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14688058     DOI: 10.1093/intimm/dxh004

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  6 in total

1.  Modification of T cell responses by stem cell mobilization requires direct signaling of the T cell by G-CSF and IL-10.

Authors:  Kelli P A MacDonald; Laetitia Le Texier; Ping Zhang; Helen Morris; Rachel D Kuns; Katie E Lineburg; Lucie Leveque; Alistair L Don; Kate A Markey; Slavica Vuckovic; Frederik O Bagger; Glen M Boyle; Bruce R Blazar; Geoffrey R Hill
Journal:  J Immunol       Date:  2014-02-28       Impact factor: 5.422

2.  Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation.

Authors:  T A Seldon; R Pryor; A Palkova; M L Jones; N D Verma; M Findova; K Braet; Y Sheng; Y Fan; E Y Zhou; J D Marks; T Munro; S M Mahler; R T Barnard; P D Fromm; P A Silveira; Z Elgundi; X Ju; G J Clark; K F Bradstock; D J Munster; D N J Hart
Journal:  Leukemia       Date:  2015-08-19       Impact factor: 11.528

3.  Targeting CD83 for the treatment of graft-versus-host disease.

Authors:  Xiongfei Wang; Ming Q Wei; Xiaosong Liu
Journal:  Exp Ther Med       Date:  2013-04-02       Impact factor: 2.447

4.  Influenza infection directly alters innate IL-23 and IL-12p70 and subsequent IL-17A and IFN-γ responses to pneumococcus in vitro in human monocytes.

Authors:  Sinead T Loughran; Patrick A Power; Paula T Maguire; Samantha L McQuaid; Paul J Buchanan; Ingileif Jonsdottir; Robert W Newman; Ruth Harvey; Patricia A Johnson
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

5.  Anti-Mouse CD83 Monoclonal Antibody Targeting Mature Dendritic Cells Provides Protection Against Collagen Induced Arthritis.

Authors:  Pablo A Silveira; Fiona Kupresanin; Adelina Romano; Wei-Hsun Hsu; Tsun-Ho Lo; Xinsheng Ju; Hsiao-Ting Chen; Helen Roberts; Daniel G Baker; Georgina J Clark
Journal:  Front Immunol       Date:  2022-02-10       Impact factor: 7.561

6.  Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease.

Authors:  John Wilson; Hannah Cullup; Rohan Lourie; Yonghua Sheng; Anna Palkova; Kristen J Radford; Anne M Dickinson; Alison M Rice; Derek N J Hart; David J Munster
Journal:  J Exp Med       Date:  2009-01-26       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.